Apellis Pharmaceuticals Inc - APLS Net earnings per one share for the last twelve months

Apellis Pharmaceuticals, Inc. (APLS) - corporate logo

The annual EPS TTM growth rate on GURU.Markets reflects profit dynamics based on the diversification of Apellis Pharmaceuticals (APLS) therapeutic platforms. A monopoly position in retinal treatment allows the company to implement premium pricing. A stable staff of scientists and the active hiring of sales managers strengthen its commercial potential. The value of 158.00 determines this parameter level, helping investors assess the efficiency of capital allocation.

APLS Apellis Pharmaceuticals: Net earnings per share (EPS TTM) in the range 02/11/2024 - 05/30/2026

Apellis Pharmaceuticals Inc - analytical breakdowns and key metrics (APLS)

- price and consensus price forecast:
Market Price apellis.com|APLS - Analyst Consensus Forecast
- issuer market value details:
Market Value Apellis Pharmaceuticals, Inc.|APLS - Total Company Value
- company book value details:
Net Assets per Share Apellis Pharmaceuticals|APLS - Book Capitalization|Market Capitalization to Book Value Ratio apellis.com|APLS - Aggregate Company Assets
- debt and liquidity data:
Aggregate Debt to Equity Apellis Pharmaceuticals|APLS - Long-Term Debt to Capital|Current Liabilities to Capital Apellis Corp|APLS - Company Debts|Debt to Book Capitalization Ratio Apellis Pharmaceuticals, Inc.|APLS - Company Long-Term Debt|Company Short-Term Debt Apellis Pharmaceuticals|Interim Coverage Ratio apellis.com
- business earnings and investment ratios data:
APLS - Company Net Income|Company Profit Forecast Apellis Pharmaceuticals|APLS - Price to Earnings Ratio|Future Price to Earnings Multiple Apellis Pharmaceuticals, Inc.|APLS - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Apellis Pharmaceuticals, Inc.|APLS - Operating profit EBITDA|Earnings per share for the trailing year Apellis Pharmaceuticals|APLS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth apellis.com|APLS - Earnings per share growth in current year|Expected earnings per share trend next year Apellis Pharmaceuticals
Initial company analysis:apellis.com - APLS
Brand item of Apellis

To isolate fundamental stability from market noise, capital requires an analysis of the rolling annual earnings per share, which measures the rate of change in net income over the last 12 months relative to the previous year. The trend of the 12-month EPS growth reflects the efficiency of business scaling, which for Apellis Pharmaceuticals (APLS) is supported by the implementation of robotic bio-screening to accelerate the development of targeted drugs.

Competitor analysis

Net earnings per one share for the last twelve months alcon.com|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Corp (GKOS)|Earnings per share for the last twelve months Belite Bio, Inc|Ocular Pharma (OCUL) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) HROW|Net earnings per share (EPS TTM) viridiantherapeutics.com (VRDN)|Earnings per share for the last twelve months LENZ Therapeutics LENZ|OCS (Oculis AG) - Earnings per one share for the last 12 months|EyePoint Pharma - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Kodiak Corp|aldeyra.com (ALDX) - Earnings per share for the last twelve months|KALA (KALA BIO) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Opus Genetics, Inc.|Earnings per share for the last twelve months OKYO|Net earnings per share (EPS TTM) ADVM|Net earnings per share for the last four quarters Outlook Therapeutics Corp|Earnings per share for the last twelve months Clearside Biomedical CLSD|Net earnings per share for the last four quarters NovaBay Pharmaceuticals Inc. (NBY)|KPRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year ALIM (Alimera Sciences)|eyenovia.com (EYEN) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months GHSI (Guardion Health)|OCUP (Ocuphire Pharma, Inc.) - Net earnings per share (EPS TTM)|OPT: Earnings per share for the trailing year